Drug Trial Radar · NCT03711162
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Last checked: Nov 20, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
525
Actual
Start
Nov 28, 2018
Primary completion
Mar 30, 2021
Study completion Mar 30, 2021
Sponsor
- Lead sponsor
- Lakefront Biotherapeutics NVIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690Drug
GLPG1690, film-coated tablets for oral use.
PlaceboDrug
Matching placebo, film-coated tablets for oral use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Rate of Decline in FVC up to Week 52Time frame: Baseline up to week 52
Locations
132 sites in 15 countries. Site status is shown where the registry gives one.
Pulmonary Associates
Phoenix, Arizona
Mayo Clinic Arizona - PPDS
Scottsdale, Arizona
Atria Clinical Research - BTC - PPDS
Little Rock, Arkansas
David Geffen School of Medicine at UCLA
Los Angeles, California
Respire Research
Palm Springs, California
University of California San Diego
San Diego, California
Stanford University Medical Center
Stanford, California
University of Colorado
Aurora, Colorado
National Jewish Health
Denver, Colorado
Western Connecticut Medical Group
Danbury, Connecticut
Yale University School of Medicine
New Haven, Connecticut
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
PAB Clinical Research - ClinEdge - PPDS
Brandon, Florida
St. Francis Medical Institute - BTC - PPDS
Clearwater, Florida
North Florida/South Georgia Veterans Health System-NAVREF-PPDS
Gainesville, Florida
University of Florida
Gainesville, Florida
Advanced Pulmonary Research Institute
Loxahatchee Groves, Florida
Northwestern Memorial Hospital
Chicago, Illinois
Pulmonary and Infections Disease Associates
Council Bluffs, Iowa
University of Louisville
Louisville, Kentucky
Tulane Medical Center
New Orleans, Louisiana
University of Maryland Medical Center
Baltimore, Maryland
Massachusetts General Hospital, Division of Pulmonary and Critical Care Medicine
Boston, Massachusetts
Caritas St. Elizabeth's Medical Center
Boston, Massachusetts
Henry Ford Health System
Dearborn, Michigan
Minnesota Lung Center
Minneapolis, Minnesota
Mayo Clinic - PPDS
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Creighton University
Omaha, Nebraska
University of Rochester Medical Center - PPDS
Rochester, New York
PulmonIx LLC
Greensboro, North Carolina
UC Health Department of Internal Medicine, Pulmonary, Critical Care & Sleep Medicine
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
The Oregon Clinic
Portland, Oregon
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.